Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
Hepatitis C causes a chronic infection in 70 percent of people but 30 percent will spontaneously clear their infection. In a subset of those people who clear their infection, they will continue to remain HCV free for many years despite recurrent exposure to virus.
What protects these people from developing chronic HCV is not understood and is a central aim of this project.
Using a cohort of injecting drug users based in Melbourne, we are studying their immune response to HCV.
This project involves examining the antibody response to viral glycoproteins over time and mapping the specificity of this antibody response.
3 years
For any general enquiries relating to this project, please contact:
Co-Program Director, Disease Elimination; Scientific Director, Burnet Diagnostics Initiative; Principal Investigator, Burnet Vaccine Initiative; Co-Head, Viral Entry and Vaccines Group
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2023 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
